Eli Lillys 203B Trade Ranks 25th as Cancer Therapy Alliance Drives Biopharma Volatility

On August 25, 2025, Eli Lilly (LLY) reported a 2.30% decline in its stock price with a trading volume of $2.03 billion, ranking 25th in market activity. The company’s recent partnership with Immuneering Corp (IMRX) has drawn market attention. Eli Lilly has entered a clinical supply agreement to provide its second-generation KRAS G12C inhibitor, olomorasib, for use in Immuneering’s Phase 2 trial of atebimetinib, a dual MEK inhibitor. The trial will evaluate the combination therapy in patients with advanced non-small cell lung cancer (NSCLC) who have progressed on prior treatments.

The collaboration builds on Immuneering’s existing partnership with Regeneron Pharmaceuticals, announced in February 2025, which tested atebimetinib with Regeneron’s anti-PD-1 therapy. Immuneering retains global development and commercialization rights to atebimetinib. Preclinical studies suggest the combination of atebimetinib and olomorasib could enhance tumor regression, delay resistance, and prolong survival compared to monotherapy. The company emphasized the potential of a pan-MAPK approach in addressing challenging tumor types like NSCLC.

Eli Lilly’s involvement in these partnerships reflects its strategic focus on advancing targeted cancer therapies. The clinical trial data and collaboration outcomes could influence future regulatory pathways and market positioning for both companies. However, the stock’s recent performance highlights ongoing volatility in the biopharma sector amid broader market dynamics.

The backtest of a strategy buying the top 500 stocks by daily trading volume and holding for one day from 2022 to 2025 yielded a 31.52% total return over 365 days. The 1-day return averaged 0.98%, with a Sharpe ratio of 0.79, indicating favorable risk-adjusted returns. The highest daily gain reached 4.95%, while the lowest loss was -4.47%. This data underscores the strategy’s ability to capture short-term momentum despite market volatility.